Caribou Biosciences (CRBU) Current Assets (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Current Assets data on file, last reported at $122.4 million in Q1 2026.

• On a quarterly basis, Current Assets fell 43.69% year-over-year to $122.4 million in Q1 2026; TTM through Mar 2026 was $122.4 million, a 43.69% decrease from a year earlier, with the FY2025 full-year figure at $145.2 million, down 33.8% from the prior year.
• Current Assets for Q1 2026 stood at $122.4 million, down from $145.2 million in the prior quarter.
• Over the last five years, Current Assets for CRBU reached as high as $368.0 million in Q1 2022 and fell as low as $122.4 million in Q1 2026.
• Historically, Current Assets has averaged $255.9 million across 5 years, with a median of $260.2 million in 2022.
• Across the five-year window, Current Assets surged 146.86% in 2022 and plunged 43.69% in 2026, its largest moves.
• Year by year, Current Assets stood at $260.2 million in 2022, then jumped by 30.2% to $338.8 million in 2023, then plunged by 35.26% to $219.4 million in 2024, then plunged by 33.8% to $145.2 million in 2025, then slipped by 15.73% to $122.4 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $122.4 million in Q1 2026, $145.2 million in Q4 2025, and $155.5 million in Q3 2025.